Spontaneous application

Stockholm

Spontaneous application

40 days left

Contact details

Emma Eklund

E-mail me

Terms

Type of employment

Tillsvidare

Working hours

Heltid

Wage conditions

Fast + rörlig

Application

Final application date

2024-06-30

Date of publication

2023-03-14

Do you want to be part of a team of outstanding individuals in a leading cell therapy company? Our culture is built on engagement, commitment and joy. We are always looking for talented individuals who wish to make a difference for the patient’s we serve.
 
XNK is a clinical-stage biotechnology company developing individualized natural killer (NK) cell-based cancer therapies. The pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors.
 
At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed a proprietary technology platform of broad utility and benefits from its tailor-made GMP facility and co-location with the Karolinska Institute and the Karolinska University Hospital. XNK is well positioned to bring transformational autologous NK cell-based therapies and new hope to cancer patients around the world.
 
Here you can register your spontaneous application.
Apply here
Final application date 2024-06-30

Do you know someone who should see this ad? Share!

About the company

XNK is a clinical-stage biotechnology company developing individualized natural killer (NK) cell-based cancer therapies. The pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors.

At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed a proprietary technology platform of broad utility and benefits from its tailor-made GMP facility and co-location with the Karolinska Institute and the Karolinska University Hospital. XNK is well positioned to bring transformational autologous NK cell-based therapies and new hope to cancer patients around the world.

Here you can register your spontaneous application.

renew access